In 2002, ABX-MA1, the MCAM monoclonal antibody (mAb), was reported to inhibit tumorigenesis and metastasis in melanoma in the xenografted mouse model; however, in the case of osteosarcoma, it did not stop tumor growth but prevented metastasis [170, 171]. Here, MCAM is linked to melanoma.